These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 420817)

  • 41. Interaction of heparin with internally quenched fluorogenic peptides derived from heparin-binding consensus sequences, kallistatin and anti-thrombin III.
    Pimenta DC; Nantes IL; de Souza ES; Le Bonniec B; Ito AS; Tersariol IL; Oliveira V; Juliano MA; Juliano L
    Biochem J; 2002 Sep; 366(Pt 2):435-46. PubMed ID: 12000310
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Heparin-like tubings. III. Kinetics and mechanism of thrombin, antithrombin III and thrombin-antithrombin complex adsorption under controlled-flow conditions.
    Migonney V; Fougnot C; Jozefowicz M
    Biomaterials; 1988 Sep; 9(5):413-8. PubMed ID: 3224126
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Heparin-catalyzed inhibitor/protease reactions: kinetic evidence for a common mechanism of action of heparin.
    Griffith MJ
    Proc Natl Acad Sci U S A; 1983 Sep; 80(18):5460-4. PubMed ID: 6577437
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The heparin-binding site of antithrombin III. Identification of a critical tryptophan in the amino acid sequence.
    Blackburn MN; Smith RL; Carson J; Sibley CC
    J Biol Chem; 1984 Jan; 259(2):939-41. PubMed ID: 6693405
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential role of fractionated heparin in antithrombin-III proteolysis.
    Marciniak E
    Blood; 1982 Mar; 59(3):576-81. PubMed ID: 7037067
    [TBL] [Abstract][Full Text] [Related]  

  • 46. On the domain structure of antithrombin III. Tentative localization of the heparin binding region using 1H NMR spectroscopy.
    Gettins P; Wooten EW
    Biochemistry; 1987 Jul; 26(14):4403-8. PubMed ID: 3663595
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Kinetics of heparin action.
    Shore JD; Olson ST; Craig PA; Choay J; Björk I
    Ann N Y Acad Sci; 1989; 556():75-80. PubMed ID: 2786689
    [No Abstract]   [Full Text] [Related]  

  • 48. Effect of monovalent cations on the heparin-enhanced antithrombin III/thrombin reaction.
    Griffith MJ; Beavers G; Kingdon HS; Lundblad RL
    Thromb Res; 1980 Jan 1-15; 17(1-2):29-39. PubMed ID: 7376137
    [No Abstract]   [Full Text] [Related]  

  • 49. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
    Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J
    J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of an abnormal antithrombin (Milano 2) with defective thrombin binding.
    Tripodi A; Krachmalnicoff A; Mannucci PM
    Thromb Haemost; 1986 Dec; 56(3):349-52. PubMed ID: 3563966
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Ultraviolet difference spectroscopy study of alpha- and beta gamma-thrombin binding to heparin].
    Semenova OA; Strukova SM
    Biokhimiia; 1980 Dec; 45(12):2225-32. PubMed ID: 7248353
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evidence by chemical modification for the involvement of one or more tryptophanyl residues of bovine antithrombin in the binding of high-affinity heparin.
    Björk I; Nordling K
    Eur J Biochem; 1979 Dec; 102(2):497-502. PubMed ID: 527591
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inactivation of alpha- and beta- thrombin by antithrombin-III and heparin.
    Machovich R; Blaskó G; Borsodi A
    Thromb Haemost; 1976 Dec; 36(3):503-8. PubMed ID: 65798
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Heparin, antithrombin, and abnormal clotting.
    Rosenberg RD
    Annu Rev Med; 1978; 29():367-78. PubMed ID: 77142
    [No Abstract]   [Full Text] [Related]  

  • 55. Demonstration of altered antithrombin III activity due to nonenzymatic glycosylation at glucose concentration expected to be encountered in severely diabetic patients.
    Villanueva GB; Allen N
    Diabetes; 1988 Aug; 37(8):1103-7. PubMed ID: 3391345
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The mechanism of anticoagulant activity of a novel heparinoid sulfated glucoside-bearing polymer.
    Sakamoto N; Kishida A; Maruyama I; Akashi M
    J Biomater Sci Polym Ed; 1997; 8(7):545-53. PubMed ID: 9195333
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The heparin-accelerated neutralisation of bovine alpha and beta thrombins by antithrombin III.
    MacGregor IR; Lane DA; Kakkar VV
    Biochim Biophys Acta; 1980 Sep; 632(1):131-7. PubMed ID: 7417517
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of heparin-catalyzed human antithrombin III activity by nonenzymatic glycosylation. Possible role in fibrin deposition in diabetes.
    Brownlee M; Vlassara H; Cerami A
    Diabetes; 1984 Jun; 33(6):532-5. PubMed ID: 6724150
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Formation, characterization and detection of a ternary complex between S protein, thrombin and antithrombin III in serum.
    Preissner KT; Zwicker L; Müller-Berghaus G
    Biochem J; 1987 Apr; 243(1):105-11. PubMed ID: 3606566
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Permeability of a heparin-polyvinyl alcohol hydrogel to thrombin and antithrombin III.
    Smith BA; Sefton MV
    J Biomed Mater Res; 1988 Aug; 22(8):673-85. PubMed ID: 3215905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.